- Report
- October 2022
- 270 Pages
Global
From €3359EUR$3,750USD£2,863GBP
- Report
- December 2022
- 150 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- July 2022
- 40 Pages
China
From €2866EUR$3,200USD£2,443GBP
- Report
- May 2024
- 137 Pages
Global
From €5821EUR$6,499USD£4,962GBP
- Report
- June 2023
- 118 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- August 2022
- 118 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- September 2021
- 111 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- April 2023
- 160 Pages
Global
From €4433EUR$4,949USD£3,779GBP
- Report
- April 2023
- 147 Pages
Global
From €4433EUR$4,949USD£3,779GBP
- Report
- February 2022
- 210 Pages
Global
From €6718EUR$7,500USD£5,726GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2463EUR$2,750USD£2,100GBP
- Report
- January 2022
- 130 Pages
Global
From €6225EUR$6,950USD£5,307GBP
- Report
- January 2022
- 90 Pages
Global
From €1791EUR$2,000USD£1,527GBP
- Report
- September 2024
- 82 Pages
Japan
From €2665EUR$2,975USD£2,271GBP
€3135EUR$3,500USD£2,672GBP
- Report
- August 2024
- 80 Pages
Japan
From €2665EUR$2,975USD£2,271GBP
€3135EUR$3,500USD£2,672GBP
- Report
- May 2024
- 185 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- April 2024
- 190 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- November 2023
- 181 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- April 2023
- 115 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- August 2022
- 111 Pages
Global
From €4255EUR$4,750USD£3,627GBP

Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients.
Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms.
The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more